Emergent BioSolutions Prepares for Financial Year Review
Emergent BioSolutions Inc. (NYSE: EBS) is gearing up to unveil its financial results for the fourth quarter and full year 2024. This important event will be held on March 3, 2025, at 5:00 pm eastern time. The conference call will allow stakeholders to gain insights into the company’s performance and outlook.
How to Participate in the Call
To ensure that interested parties can join, Emergent BioSolutions has arranged a live conference call. Participants can easily access the call by visiting the Investor page on Emergent's official website and registering in advance. Telephone participants will receive a confirmation email which includes all necessary details to access the call.
Replay Access and Investor Events
For those who cannot attend the live call, a replay will be made available shortly after the event concludes. This replay can also be accessed through the Investor section on Emergent’s website, providing a convenient way for investors to stay updated on the company's performance.
Upcoming Presentation at J.P. Morgan’s Conference
In addition to the financial call, Emergent will take part in J.P. Morgan’s 2025 Leveraged Finance Conference. This event is slated for February 24, 2025, at 11:00 am eastern time. Participants can expect a brief presentation illuminating the company's strategy and initiatives.
Overview of Emergent BioSolutions
Emergent BioSolutions has been a pillar in the public health landscape for over 25 years. Their mission is clear: to protect and enhance life. Through a diverse portfolio of vaccines and therapeutics, the company is committed to addressing urgent public health threats. They not only develop innovative solutions but also provide contract development and manufacturing services tailored for pharmaceutical and biotechnology clients.
Aiming to Impact a Billion Lives
Emergent has set an ambitious goal to protect or enhance the lives of one billion people by 2030. This commitment underscores their dedication to innovation and public health, ensuring that they are well-prepared for future challenges.
Contact Information and Further Studies
For those wishing to learn more about Emergent BioSolutions or have any inquiries regarding investor relations, Richard S. Lindahl, the Executive Vice President and CFO, is the designated contact. His email address is provided for direct communication.
Media Inquiries
Furthermore, for media-related queries, Assal Hellmer, the Vice President of Communications at Emergent, is available. Both contacts can facilitate further engagement for stakeholders and media alike.
Frequently Asked Questions
When will Emergent BioSolutions hold its financial call?
The financial call is scheduled for March 3, 2025, at 5:00 pm eastern time.
How can I participate in the conference call?
Participation is via registration on Emergent’s Investor page, and participants will receive email confirmation with instructions.
Will there be a replay of the financial call?
Yes, a replay of the call will be available on the Investor section of Emergent’s website shortly after the live event.
What other events is Emergent participating in?
Emergent will also present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025, at 11:00 am eastern time.
How does Emergent BioSolutions aim to impact public health?
Emergent is focused on developing vaccines and therapeutics to address urgent public health challenges and has set a goal to protect or enhance one billion lives by 2030.
